Multidrug-Resistant Orthopaedic Surgical Site Infections Treated with Linezolid in Four Dogs

Abstract

Objective This study aimed to report the adverse drug events and treatment outcome of systemic linezolid therapy to manage multi-drug resistant orthopaedic surgical site infection in dogs.

Materials and Methods Retrospective case review of four dogs that received linezolid to treat surgical site infections after orthopaedic surgery. Reevaluations consisted of a clinical examination or a telephone interview.

Results Serum drug concentrations varied. All dogs showed a temporary resolution of clinical signs of surgical site infection. Two dogs that received linezolid at the previously reported dose developed drug-associated side effects. The side effects were anorexia, nausea, vomiting and regenerative anaemia. All side effects resolved after the discontinuation of linezolid. Surgical site infection recurred in two dogs 52 and 177 days after discontinuing linezolid respectively.

Clinical significance Adverse drug events occurred in dogs receiving oral linezolid at the dosage of 10 to 20 mg/kg. Oral linezolid therapy failed to resolve deep orthopaedic surgical site infections in two out of four dogs. As a tertiary antimicrobial, linezolid should only be used in carefully selected cases while monitoring for drug-associated side effects.

Keywords

infections - multiresistant bacteria - surgical site infection - dog - linezolid

Authors' Contributions

P.-Y.C., D.J.M.-L., and R.A.H.-B., contributed to case management and follow-up interview or examination. J.Y. contributed to data collection. P.-Y.C. and D.J.M.-L. contributed to manuscript preparation. R.H.-B. contributed to manuscript revision.

^* J.Y.’s current workplace is VCA West Coast Specialty and Emergency Animal Hospital, Orange County, California, United States. R.A.H-B’s current workplace is the Sam’s Clinic, Marin, California, United States.

Publikationsverlauf

Eingereicht: 19. Februar 2020

Angenommen: 08. Juni 2020

Artikel online veröffentlicht:
05. August 2020

• References

• 1 Roger C, Roberts JA, Muller L. Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin Pharmacokinet 2018; 57 (05) 559-575
• 2 Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004; 23 (02) 113-119
• 3 Foster JD, Trepanier LA, Ginn JA. Use of linezolid to treat MRSP bacteremia and discospondylitis in a dog. J Am Anim Hosp Assoc 2014; 50 (01) 53-58
• 4 Papich MG, Papich MG. Selection of antibiotics for methicillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs?. Vet Dermatol 2012; 23 (04) 352-360 , e64
• 5 Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clin Proc 2004; 79 (09) 1137-1144
• 6 Slatter JG, Adams LA, Bush EC. , et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002; 32 (10) 907-924
• 7 Pea F, Furlanut M, Cojutti P. , et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54 (11) 4605-4610
• 8 Rubinstein E, Isturiz R, Standiford HC. , et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47 (06) 1824-1831
• 9 Bishop E, Melvani S, Howden BP, Charles PGP, Grayson ML. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50 (04) 1599-1602
• 10 Pfizer. Zyvox (linezolid) prescribing information; 2015. Available from: http://labeling.pfizer.com/showlabeling.aspx?id=649 . Accessed April 13, 2020
• 11 Legout L, Valette M, Dezeque H. , et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?. J Antimicrob Chemother 2010; 65 (10) 2224-2230
• 12 Soriano A, Gómez J, Gómez L. , et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007; 26 (05) 353-356
• 13 Wang T, Guo D, Dong X, Mu L. Effect of linezolid on hematological and oxidative parameters in rats. J Antibiot (Tokyo) 2014; 67 (06) 433-437
• 14 Moore JE, Heaney N, Millar BC, Crowe M, Elborn JS. Incidence of Pseudomonas aeruginosa in recreational and hydrotherapy pools. Commun Dis Public Health 2002; 5 (01) 23-26
• 15 Cain CL, Mauldin EA. Clinical and histopathologic features of dorsally located furunculosis in dogs following water immersion or exposure to grooming products: 22 cases (2005-2013). J Am Vet Med Assoc 2015; 246 (05) 522-529
• 16 Hayes G, Moens N, Gibson T. A review of local antibiotic implants and applications to veterinary orthopaedic surgery. Vet Comp Orthop Traumatol 2013; 26 (04) 251-259
• 17 Thomas LA, Bizikova T, Minihan AC. In vitro elution and antibacterial activity of clindamycin, amikacin, and vancomycin from R-gel polymer. Vet Surg 2011; 40 (06) 774-780
• 18 Shaw KA, Eichinger JK, Nadig N, Parada SA. In vitro effect of vancomycin on the viability of articular chondrocytes. J Orthop Trauma 2018; 32 (03) 148-153
• 19 Edin ML, Miclau T, Lester GE, Lindsey RW, Dahners LE. Effect of cefazolin and vancomycin on osteoblasts in vitro. Clin Orthop Relat Res 1996; 333: 245-251